Research Article
Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study
| | (%) |
| Cancer therapy | = 405 | (i) First-line chemotherapy alone | 169 (41.7%) | (ii) First-line targeted therapy alone* | 24 (5.9%) | (iii) First-line combined therapy (chemotherapy and targeted therapy) | 163 (40.2%) | (iv) Second-line therapy (chemotherapy and/or targeted therapy) | 128 (31.6%) | First-line chemotherapy alone | = 169 | (i) Anthracycline-based | 84 (49.7%) | (ii) Non-anthracycline-based | 85 (50.3%) | (iii) Median anthracycline dose | 277 mg/m2 (r: 46–4803) | Number of chemotherapy cycles (median) | | (i) First-line chemotherapy | 6 (r: 0–59 cycles) | (ii) Second-line chemotherapy | 5.5 (r: 0–33 cycles) |
|
|
Targeted therapy examples: trastuzumab, sunitinib, bevacizumab, sorafenib, and imatinib.
|